How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Arcutis Biotherapeutics now sits at the center of a fairly tight cluster of Street price targets, with several analysts coalescing around about $35 after recent model updates. Those tweaks, which include both upward and downward revisions into the mid $30s, are being tied directly to Q4 results, refreshed guidance, and evolving views on the Zoryve rollout. As you read on, you will see how these small shifts feed into the broader analyst narrative and what to watch as new data points emerge.

Stay updated as the Fair Value for Arcutis Biotherapeutics shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Arcutis Biotherapeutics.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Morgan Stanley, TD Cowen, Guggenheim, and H.C. Wainwright all recalibrated their models around a similar $35 area, signaling that recent Q4 data and guidance are feeding into a more aligned view of Arcutis Biotherapeutics' valuation. Morgan Stanley cited Q4 sales that came in ahead of expectations and referenced higher full year net product revenue guidance, which supports its Overweight stance on the shares. TD Cowen and Guggenheim both lifted their targets, with TD Cowen tying the move to model updates after Q4 results and higher full year 2026 guidance, and Guggenheim pointing to being encouraged by the trajectory of Zoryve and commercialization efforts. H.C. Wainwright raised its target to $34 and described the Q4 report as strong, which adds to the cluster of firms expressing confidence in recent execution.

🐻 Bearish Takeaways

Mizuho moved its target down to $35 from $37 after revisiting its model post Q4, which highlights that not all firms see incremental upside at prior valuation levels even as they maintain positive ratings.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!NasdaqGS:ARQT 1-Year Stock Price Chart

We've flagged 1 risk for Arcutis Biotherapeutics. See which could impact your investment.

What's in the News

New Phase 2 INTEGUMENT-INFANT data for ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis showed reductions in signs and symptoms, with 49% of completers reaching a vIGA-AD score of Clear or Almost Clear and 58.3% achieving EASI-75 at Week 4, and a supplemental NDA submission is planned for Q2 2026. Pediatric Dermatology published long term Phase 3 INTEGUMENT-OLE data in children aged 2 to 5 years with mild to moderate atopic dermatitis, reporting ZORYVE cream 0.05% as safe and well tolerated for up to 56 weeks, with 63.1% of completers achieving a vIGA-AD score of Clear or Almost Clear and EASI-75 rates above 70% at Week 56. Arcutis initiated a Phase 1a/1b double blind, randomized, placebo controlled study of ARQ-234, a CD200 receptor agonist fusion protein, in about 125 adults and healthy volunteers with moderate to severe atopic dermatitis to assess safety, tolerability, pharmacokinetics, and proof of concept. The company updated its 2026 net product revenue guidance to a range of US$480m to US$495m, compared with the prior range of US$455m to US$470m.

Story Continues

How This Changes the Fair Value For Arcutis Biotherapeutics

Fair value remains at US$34.75 as the central estimate in the model. The revenue growth assumption adjusts from 27.69% to 27.78%. The net profit margin assumption shifts from 34.01% to 33.92%. The future P/E multiple moves from 22.31x to 22.36x. The discount rate changes from 7.14% to 7.21%.

Never Miss an Update: Follow The Narrative

Narratives link a company's real world story to a financial forecast and fair value, updating as new data, guidance, and research come through. They help you see how product, industry, and risk developments fit together in one clear view.

Head over to the Simply Wall St Community and follow the Narrative on Arcutis Biotherapeutics to stay up to date on:

How expanded ZORYVE indications, partnerships, and broader insurance coverage are being used to tap large, currently underserved dermatology populations. Why demand for non steroidal treatments, an aging population, and ongoing R&D for adjacent indications feature prominently in analyst growth expectations. How dependence on the ZORYVE franchise, payer and reimbursement uncertainty, high ongoing spending, and a relatively limited pipeline shape the key risks analysts are watching.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ARQT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments